Mechanisms of action of statins and their pleiotropic effects;Mécanismes d'action des statines et leurs effets pléiotropes

Annales d'Endocrinologie

Volumn 62, Issue 2, 2001, Pages 101-112

  Davignon, J ^a   Mabile, L ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Atherosclerosis; Cancer; Endothelial function; Inflammation; Osteoporosis; Pleiotropic effect; Statins; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BEZAFIBRATE; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; CERIVASTATIN; CIPROFIBRATE; CLOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 4; MEVINOLIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHONIC ACID DERIVATIVE; PLACEBO; PRAVASTATIN; PROSTAGLANDIN SYNTHASE; SIMVASTATIN;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BONE DEVELOPMENT; CANCER; CELL CYCLE; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIUM LESION; HUMAN; LIPOPHILICITY; LIPOPROTEIN BLOOD LEVEL; OSTEOPOROSIS; PLEIOTROPY; PRENYLATION; REVIEW;

ARTERIOSCLEROSIS; CELL DIVISION; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; LOVASTATIN; NEOPLASMS; OSTEOPOROSIS;

EID: 17044448335     PISSN: 00034266     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (124)

1. Protein prenylation : Molecular mechanisms and functional consequences
2. The L-arginine-nitric oxide pathway: Role in atherosclerosis and therapeutic implications
3. Endothelial dysfunctions : Common denominators in vascular disease
4. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries
5. The 1996 Albert Lasker Medical Research Awards. The discovery of endothelium-derived relaxing factor and its importance in the identification of nitric oxide
6. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease
7. Attenuation of acetylcholine-induced vasoconstriction by L-arginine is related to the progression of atherosclerosis
8. Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries
9. Membrane active lipids in remnant lipoproteins cause impairment of endothelium-dependent vasorelaxation
10. Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level
11. Does lipoprotein(a) impair endothelial function?
12. Dietary vitamin E increases the resistance to lipoprotein oxidation and attenuates endothelial dysfunction in the cholesterol-fed rabbit
13. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans
14. Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men
15. Inhibitory effects of low-density lipoproteins from men with type II diabetes on endothelium-dependent relaxation
16. Hemodialysis impairs endothelial function via oxidative stress - Effects of vitamin E-coated dialyzer
17. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia
18. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease
19. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion
20. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease : A potential noninvasive marker of healing coronary endothelium
21. Low-density lipoprotein-independent effects of statins
22. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease
23. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
24. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase
25. Reductase inhibitor monotherapy and stroke prevention
26. Effect of HMGcoA reductase inhibitors on stroke - A meta-analysis of randomized, controlled trials
27. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions
28. Improvement of coronary vasodilatation capacity through single LDL apheresis
29. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys
30. Improvement of vascular reactivity during pravastatin treatment is affected by circulating nitric oxide inhibitor (ADMA) levels in young adults
31. L-arginine prevents xanthoma development and inhibits atherosclerosis in LDL receptor knockout mice
32. Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in apolipoprotein E-deficient mice
33. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease
34. Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: A double-blind study
35. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month
36. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes - The RECIFE (Reduction of cholesterol in ischemia and function of the endothelium) trial
37. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates Atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction
38. Mechanisms of disease - Atherosclerosis - An inflammatory disease
39. Cortisone and experimental atherosclerosis
40. C-reactive protein and cardiovascular disease
41. Prospective studies of C-reactive protein as a risk factor for cardiovascular disease
42. C Reactive protein and its relation to cardiovascular risk factors: A population based cross sectional study
43. C-Reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
44. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men - Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992
45. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
46. Chronic subclinical inflammation as part of the insulin resistance syndrome - The Insulin Resistance Atherosclerosis Study (IRAS)
47. Statins and C-reactive protein
48. Thermal heterogeneity within human atherosclerotic coronary arteries detected in vivo - A new method of detection by application of a special thermography catheter
49. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hypercholesterolemic rats
50. Importance of endothelial function in mediating the benefits at lipid-lowering therapy
51. Inhibition of monocyte chemotactic protein-1 synthesis by statins
52. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae
53. Effect of fluvastatin sodium on the smooth muscle cells in atherosclerotic plaques - In vivo study using low-density lipoprotein receptor deficient Watanabe heritable hyperlipidemic (WHHL) rabbits
54. An HMGCoA reductase inhibitor (cerivastatin) suppresses accumulation of macrophages expressing matrix metalloproteinases and tisue factor in atheroma of WHHL rabbits
55. Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits
56. Pleiotropic effects of statins in atherosclerosis and diabetes
57. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, matrix metalloproteinases and cell death in human carotid plaques favoring lesion stability
58. Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors: Comparison with other human cell types
59. The pleiotropic effects of drugs affecting lipid metabolism
60. Methods and endpoint issues in clinical development of lipid-acting agents with pleiotropic effects
61. Kip1
62. Cholesterol inhibition, cancer, and chemotherapy
63. Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase
64. Growth inhibition of neuroblastoma cells by lovastatin and L-ascorbic acid is based on different mechanisms
65. Metastasis of B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesis
66. Lovastatin induces apoptosis in malignant mesothelioma cells
67. Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation
68. Action of lovastatin, simvastatin, and pravastatin on sterol synthesis and their antiproliferative effect in cultured myoblasts from human striated muscle
69. Simvastatin impairs mitogen-induced proliferation of malignant B- lymphocytes from humans - In vitro and in vivo studies
70. The sensitivity of leukemic bone marrow to simvastatin is lost at remission : A potential purging agent for autologous bone marrow transplantation
71. Increased sensitivity of acute myeloid leukemias to lovastatin- induced apoptosis : A potential therapeutic approach
72. Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells
73. A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors
74. Cell cycle-specific effects of lovastatin
75. Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis
76. Stimulation of human breast cancer MCF-7 cells with estrogen prevents cell cycle arrest by HMG-CoA reductase inhibitors
77. Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion
78. Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats
79. Low density lipoproteins and Lovastatin modulate the organ- specific transendothelial migration of primary and metastatic human colon adenocarcinoma cell lines in vitro
80. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac
81. ras isoprenylation, of hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats
82. All ras proteins are polyisoprenylated but only some are palmitoylated
83. p21ras is modified by a farnesyl isoprenoid
84. Translational control of p27Kip1 accumulation during the cell cycle
85. Geranylgeranylated rho small GTPase(s) are essential for the degradation of p27Kip1 and facilitate the progression from G1 to S phase in growth-stimulated rat FRTL-5 cells
86. Lovastatin induces apoptosis by inhibiting mitotic and post- mitotic events in cultured mesangial cells
87. 1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase
88. Lovastatin inhibits proliferation and differentiation and causes apoptosis in lipopolysaccharide-stimulated murine B cells
89. The effects of pravastatin, an HMG-CoA reductase inhibitor, on cell viability and DNA production of rat hepatocytes
90. HMG-CoA reductase inhibitors induce apoptosis in mouse proximal tubular cells in primary culture
91. Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells
92. 3-hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture
93. Lovastatin induces fibroblast apoptosis in vitro and in vivo - A possible therapy for fibroproliferative disorders
94. Lovastatin sensitizes colon cancer HT-29 cells to apoptosis induced by chemotherapeutic agents
95. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP
96. Lovastatin inhibits platelet-derived growth factor (PDGF) stimulation of phosphatidylinositol 3-kinase activity as well as association of p85 subunit to tyrosine-phosphorylated PDGF receptor
97. Simvastatin inhibits the cellular signaling and proliferative action of arginine vasopressin in cultured rat glomerular mesangial cells
98. Lovastatin inhibits the stimulation of mitogen-activated protein kinase by insulin in HIRcB fibroblasts
99. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study
100. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
101. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
102. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
103. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS
104. Lipid-lowering medication and risk of cancer
105. Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice
106. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
107. Aspirin use and reduced risk, of fatal colon cancer
108. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis
109. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor
110. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors
111. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect : Reduction of MRNA levels for interleukin- 1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator- activated receptor alpha (PPARalpha) in primary endothelial cells
112. Lovastatin and tumor necrosis factor-α exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis
113. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering
114. The osteoporosis revolution
115. Stimulation of bone formation in vitro and in rodents by statins
116. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells
117. Alendronate mechanism of action : Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro
118. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase
119. Do statins prevent both cardiovascular disease and fracture?
120. HMG-CoA reductase inhibitors and the risk of fractures
121. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients
122. Regulation of the mevalonate pathway
123. Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteins
124. Sterols and isoprenoids : Signaling molecules derived from the cholesterol biosynthetic pathway